ReviewTranslational gastroenterology and hepatology2017
Bridging patients with hepatocellular cancer waiting for liver transplant: all the patients are the same?
Review in Translational gastroenterology and hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Comparison between Trans-Arterial Chemoembolization Followed by Stereotactic Body Radiation Therapy and Trans-Arterial Chemoembolization Alone in BCLC Stage B Hepatocellular Carcinoma: A Pilot Study.Asian Pacific journal of cancer prevention : APJCP · 2024Trial
- Association of LR treatment response category with outcome of patients with hepatocellular carcinoma on explant pathology.Abdominal radiology (New York) · 2025Article
- Immunotherapy before liver transplant in unresectable hepatocellular carcinoma: a case report.Journal of gastrointestinal oncology · 2023Article
- Nurses' comfort care of transarterial chemoembolization patients based on their perceptions around postembolization syndrome and symptom interference.Nursing open · 2023Article
- The Role of Ablative Techniques in the Management of Hepatocellular Carcinoma: Indications and Outcomes.Biomedicines · 2023Review
- Management of Hepatocellular Carcinoma in Decompensated Cirrhotic Patients: A Comprehensive Overview.Cancers · 2023Review
- Microspheres as a Carrier System for Therapeutic Embolization Procedures: Achievements and Advances.Journal of clinical medicine · 2023Review
- Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma.Oncoimmunology · 2023Review
- Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review.Cureus · 2022Review
- Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors.Cancers · 2021Review
- Microfluidic-based fabrication and characterization of drug-loaded PLGA magnetic microspheres with tunable shell thickness.Drug delivery · 2021Article
- Conventional versus drug-eluting bead transarterial chemoembolization: A better option for treatment of unresectable hepatocellular carcinoma.Journal of interventional medicine · 2021Review
- Tumor grade may be used to select patients with multifocal hepatocellular carcinoma for resection.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2020Article
- Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions.Digestive disease interventions · 2020Article
- Gli3 is a novel downstream target of miR‑200a with an anti‑fibrotic role for progression of liver fibrosis in vivo and in vitro.Molecular medicine reports · 2020Article
- Review
- Downregulation of miR-152 contributes to the progression of liver fibrosis via targeting Gli3Experimental and therapeutic medicine · 2019Article
- Recent innovations in the management of hepatocellular cancer in the setting of liver transplantation: preface.Translational gastroenterology and hepatology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver transplant (LT) is considered the best curative treatment for patients with cirrhosis and hepatocellular carcinoma (HCC) within Milan criteria. The possibility to perform LT in HCC patients is limited by the liver grafts supply; indeed, the shortage of donors often leads to a long time on waiting list and then to dropout because of tumor progression. Bridging therapies are neo-adjuvant treatments given to patients on LT waitlist, with the aim to prevent tumor progression and to reduce dropout rate. Many bridging modalities have been proposed. The choice of each treatment is based on the characteristics of the patient, liver function, comorbidities and on the number, dimensions and localization of HCC. This review article describes several types of bridging therapies, focusing on the indications for different kind of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.